
Gene Editing Therapy Receives FDA Fast Track Status in Aiming For Potential Chronic HBV Cure
The FDA granted a fast track designation to clinical stage gene editing company, Precision BioSciences, for its investigational gene therapy, PBGENE-HBV. This in vivo gene editing program was developed to cure chronic hepatitis B by eliminating cccDNA, the …